Top Markets
Coin of the day
Actuate Therapeutics Inc Actuate Therapeutics Inc

Actuate Therapeutics Inc

ACTU
Pozycja w akcjach #28698
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the... Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Cena akcji
$1.05
Kapitalizacja rynkowa
$25.12M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-86.83%
Kraj
US
Handel Actuate Therapeutics Inc (ACTU)

Kategoria

Historia stopy dywidendy dla Actuate Therapeutics Inc (ACTU)
Stopa dywidendy (TTM) dla Actuate Therapeutics Inc (symbol akcji: ACTU) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Actuate Therapeutics Inc (ACTU) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji